These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 15963333)

  • 1. Cardiovascular and Endothelial Disease in HIV Infection.
    Cespedes MS; Aberg JA
    Curr Infect Dis Rep; 2005 Jul; 7(4):309-315. PubMed ID: 15963333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV disease is associated with increased biomarkers of endothelial dysfunction despite viral suppression on long-term antiretroviral therapy in Botswana.
    Mosepele M; Mohammed T; Mupfumi L; Moyo S; Bennett K; Lockman S; Hemphill LC; Triant VA
    Cardiovasc J Afr; 2018 May/Jun 23; 29(3):155-161. PubMed ID: 29771268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus.
    Grinspoon SK
    Am J Med; 2005 Apr; 118 Suppl 2():23S-28S. PubMed ID: 15903292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic and Cardiovascular Complications in HIV/HCV-Co-infected Patients.
    Bedimo R; Abodunde O
    Curr HIV/AIDS Rep; 2016 Dec; 13(6):328-339. PubMed ID: 27595755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
    Sturt AS; Dokubo EK; Sint TT
    Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelial dysfunction in HIV infection.
    Cotter BR
    Curr HIV/AIDS Rep; 2006 Sep; 3(3):126-31. PubMed ID: 16970839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular dysfunction and cardiovascular complications.
    Triant VA; Grinspoon SK
    Curr Opin HIV AIDS; 2007 Jul; 2(4):299-304. PubMed ID: 19372902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current update on HIV-associated vascular disease and endothelial dysfunction.
    Mu H; Chai H; Lin PH; Yao Q; Chen C
    World J Surg; 2007 Apr; 31(4):632-43. PubMed ID: 17372667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reviewing the cardiovascular complications of HIV infection after the introduction of highly active antiretroviral therapy.
    Barbaro G
    Curr Drug Targets Cardiovasc Haematol Disord; 2005 Aug; 5(4):337-43. PubMed ID: 16101566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular risk and endothelial function in people living with HIV/AIDS: design of the multi-site, longitudinal EndoAfrica study in the Western Cape Province of South Africa.
    Strijdom H; De Boever P; Walzl G; Essop MF; Nawrot TS; Webster I; Westcott C; Mashele N; Everson F; Malherbe ST; Stanley K; Kessler HH; Stelzl E; Goswami N
    BMC Infect Dis; 2017 Jan; 17(1):41. PubMed ID: 28061822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The metabolic and cardiovascular consequences of obesity in persons with HIV on long-term antiretroviral therapy.
    Koethe JR; Grome H; Jenkins CA; Kalams SA; Sterling TR
    AIDS; 2016 Jan; 30(1):83-91. PubMed ID: 26418084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Abnormal body fat distribution and type of antiretroviral therapy as predictors of cardiovascular disease risk in HIV-infected patients].
    Ena J; Benito C; Llácer P; Pasquau F; Amador C
    Med Clin (Barc); 2004 May; 122(19):721-6. PubMed ID: 15171905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin resistance in the HIV-infected population: the potential role of mitochondrial dysfunction.
    Shikuma CM; Day LJ; Gerschenson M
    Curr Drug Targets Infect Disord; 2005 Sep; 5(3):255-62. PubMed ID: 16181144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic and skeletal complications of HIV infection: the price of success.
    Morse CG; Kovacs JA
    JAMA; 2006 Aug; 296(7):844-54. PubMed ID: 16905789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-associated vascular diseases: structural and functional changes, clinical implications.
    Monsuez JJ; Charniot JC; Escaut L; Teicher E; Wyplosz B; Couzigou C; Vignat N; Vittecoq D
    Int J Cardiol; 2009 Apr; 133(3):293-306. PubMed ID: 19131130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection.
    Barbaro G
    Curr HIV Res; 2006 Jan; 4(1):79-85. PubMed ID: 16454713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atherosclerotic vascular disease in HIV: it is not just antiretroviral therapy that hurts the heart!
    van Leuven SI; Sankatsing RR; Vermeulen JN; Kastelein JJ; Reiss P; Stroes ES
    Curr Opin HIV AIDS; 2007 Jul; 2(4):324-31. PubMed ID: 19372907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular effects of antiretroviral therapy and noninvasive assessments of cardiovascular disease in HIV infection.
    Cotter BR; Torriani FJ
    Cardiovasc Toxicol; 2004; 4(3):281-6. PubMed ID: 15470275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.